Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Osimertinib With Intracranial Stereotactic Radiotherapy for Newly Diagnosed, Treatment Naive EGFR Mutation Non-Small Cell Lung Cancer With Symptomatic Brain Metastases: A Retrospective, Multicenter, Real-world Study

NCT07491211 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07491211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Osimertinib With Intracranial Stereotactic Radiotherapy for Newly Diagnosed, Treatment Naive EGFR Mutation Non-Small Cell Lung Cancer With Symptomatic Brain Metastases: A Retrospective, Multicenter, Real-world Study
Lead sponsor
Fudan University
Phase
Observational
Overall status
Active, not recruiting
Start date
July 19, 2019
Completion date
March 31, 2026
Enrollment
300 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases from non-small cell lung cancer (nsclc), nsclc (advanced non-small cell lung cancer), osimertinib, stereotactic radiation